Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

CancerIQ

Request full access

CancerIQ harnesses big data to accelerate personalized cancer care

Chicago, United StatesFounded 2013Health

About CancerIQ

CancerIQ operates within the specialized field of precision cancer prevention, offering a platform designed to assist healthcare providers in identifying, evaluating, and managing patients who are at a heightened risk for hereditary cancer. The company was co-founded in 2013 by Olufunmilayo I. Olopade, MD, a distinguished oncologist and expert in cancer genetics, and her daughter, Feyi Olopade Ayodele, who serves as the CEO. The inception of the company is rooted in Dr. Olopade's extensive clinical and research experience at the University of Chicago, where she recognized the critical gap between genetic discoveries and their practical application in patient care.

Feyi Olopade Ayodele brings a complementary background in business and finance to the company. Holding an MBA from The Wharton School, her expertise has been instrumental in navigating the complex healthcare market and scaling the company's operations. This mother-daughter partnership combines deep clinical and genetic knowledge with strategic business acumen, directly addressing the challenge of integrating genetic risk assessment into routine clinical workflow.

The company's core offering is a software platform that automates the process of identifying at-risk patients through screening questionnaires, pedigree analysis, and the integration of genetic test results. This system streamlines what is traditionally a time-consuming and manual process, allowing clinicians to more efficiently determine who may benefit from genetic counseling and testing. The platform serves a diverse client base, including hospitals, cancer centers, and women's health clinics. CancerIQ's business model is primarily based on a subscription-based software-as-a-service (SaaS) model, where healthcare organizations pay for access to the platform to manage their high-risk patient populations effectively.

By providing tools that support early detection and preventative care, CancerIQ aims to shift the paradigm from reactive cancer treatment to proactive cancer risk management. The platform facilitates guideline-based care, helping providers to create personalized care plans for high-risk individuals, which may include increased surveillance, risk-reducing medications, or preventative surgeries. The company has secured multiple rounds of funding, including a notable $14 million Series B financing round, to expand its technology and market reach.

Source: Dealroom company data

At a glance

Status
Operational
Employees
32
Open positions
None listed
Dealroom signal
68.6/100
Industry
Health
Sector
Testing, Risk Management, Oncology, DNA, Genetics and genomics, Patient Care, Spinout, Genome Engineering, medical testing, DT and LS
Technology
Big Data, Deep Tech
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GROWTH EQUITY VC✓Equity / VC Aug 2024 $0 — Decathlon Capital Partners ↗
SERIES B✓Equity / VC Mar 2022 $14M $56M Merck Global Health Innovation Fund · HealthX Ventures · Amgen Ventures · OSF Ventures ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

CancerIQ website traffic

Latest recorded traffic for CancerIQ is 22K monthly website visits, down 18.5% over the last three months. CancerIQ's team declined 8.6% over the past year.

Latest monthly visits22K 3-month web change-18.5% 1-year team growth-8.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
RepairogenRepairogen employs proprietary DNA-repair technologies to create advanced, scientifically-proven skincare products New York City, United States Operational 2 $1.5M $4M
Pear TherapeuticsPear discovers, develops, and commercializes Prescription Digital Therapeutics to treat diseases with high unmet need Boston, United States Operational
Multiplicom#Multiplicom is the leading Belgian biotech company that develops, manufactures and commercializes molecular diagnostic tests that enable personalized medicine Antwerp, Belgium Acquired
Empire GenomicsLeader in the field of molecular diagnostic services for oncology diseases Cheektowaga, United States Acquired
ToxysProvides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development Leiden, Netherlands Operational
NeoChordNeoChord, a medical device company, develops devices that allow mitral valve repair to be performed on a beating heart Blackstone, United States Operational
Kailos GeneticsConsumers access to affordable physician-ordered genetic tests Huntsville, United States Acquired
Strand Life SciencesStrand is leading a new generation of healthcare defined by genetic insights into disease Bengaluru, India Acquired
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

CancerIQ in the Chicago ecosystem

Live from Dealroom

The CancerIQ office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

Series A5 investors entered at this stage

  • Impact Engine
  • HealthX Ventures
  • Merck Global Health Innovation Fund
  • Amgen Ventures
  • OSF Ventures

Series B and later1 investor entered at this stage

  • Decathlon Capital Partners

Other known investors6 additional known investors

  • The University of Chicago
  • 76 Forward
  • Lightbank
  • McKesson Ventures
  • OSF
  • Rock Health Capital
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States96%
🇦🇺 Australia4%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about CancerIQ on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CancerIQ’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.